CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference

ATLANTA, Nov. 6, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that Steven G. Anderson , president and chief executive officer of CryoLife, Inc., is scheduled to present in the upcoming Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 3:00 pm ET in New York City. 

CryoLife's live presentation may be accessed through its Web site, www.cryolife.com, on the Investor Relations page.  An archived copy of the presentation will be available for 90 days on the same Web site.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europe, and Canada.  CryoLife's CryoValve^® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft^® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch^® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of congenital heart defects.  CryoLife's BioGlue^® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and is approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife's subsidiary Hemosphere, Inc. markets the HeRO^® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot^®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam^™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

For additional information about the company, visit CryoLife's website:
http://www.cryolife.com.

Contacts:

SOURCE CryoLife, Inc.

RELATED LINKS
http://www.cryolife.com